Predict your next investment

Corporate Venture
gtimvc.com.cn

See what CB Insights has to offer

Investments

11

Portfolio Exits

1

Funds

1

About General Technology Venture Capital

General Technology Venture Capital (GTVC) is the venture capital subsidiary of Genertec Investment Management, focusing on growth-stage start-ups.

General Technology Venture Capital Headquarter Location

Zhongguancun Science and Technology Park Haidian District

Beijing, Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest General Technology Venture Capital News

QuantiHealth Raises $3.2 Million in Pre-A Financing - ChinaBio® Today

Oct 12, 2015

QuantiHealth Raises $3.2 Million in Pre-A Financing publication date: Oct 11, 2015 QuantiHealth, a Beijing biotech services company focusing on molecular health testing and related applications, completed a $3.2 million round pre-A financing led by General Technology Venture Capital of China. Using molecular detection techniques, QuantiHealth provides comprehensive health detection and monitoring services to various health agencies. The company indicated that the funds will be used for basic data collection, market expansion, research and development of micro-ecological intervention products. More details.... Share this with colleagues: This article is available for purchase - please click here for details. Sorry... this feature or article is only available to subscribers.

General Technology Venture Capital Investments

11 Investments

General Technology Venture Capital has made 11 investments. Their latest investment was in Yikon Genomics as part of their Series D on May 5, 2021.

CBI Logo

General Technology Venture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/6/2021

Series D

Yikon Genomics

$38.87M

Yes

1

6/21/2019

Series D

Percutek Therapeutics

$14.55M

Yes

1

4/17/2019

Series E

7LeKang

Yes

1

11/14/2017

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/5/2016

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

5/6/2021

6/21/2019

4/17/2019

11/14/2017

7/5/2016

Round

Series D

Series D

Series E

Series B

Seed VC

Company

Yikon Genomics

Percutek Therapeutics

7LeKang

Subscribe to see more

Subscribe to see more

Amount

$38.87M

$14.55M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

General Technology Venture Capital Portfolio Exits

1 Portfolio Exit

General Technology Venture Capital has 1 portfolio exit. Their latest portfolio exit was Longshen Rongfa on September 13, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/13/2016

IPO

1

Date

9/13/2016

Exit

IPO

Companies

Valuation

Acquirer

Sources

1

General Technology Venture Capital Fund History

1 Fund History

General Technology Venture Capital has 1 fund, including Dingxing Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Dingxing Fund

Multi-Stage Venture Capital

Closed

1

Closing Date

Fund

Dingxing Fund

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

Sources

1

General Technology Venture Capital Team

1 Team Member

General Technology Venture Capital has 1 team member, including current Chief Executive Officer, Chunhai Lin.

Name

Work History

Title

Status

Chunhai Lin

Chief Executive Officer

Current

Name

Chunhai Lin

Work History

Title

Chief Executive Officer

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.